Erfolgreich hinzugefügt!
Kursdaten 
Chart
News + Analysen
Fundamental
Unternehmen
Derivate
Aktion
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 98,63 |
| Government Pension Fund - Global (The) | 2,81 |
| Roche Holding AG | 1,34 |
| Vanguard Total International Stock Index Fund | 1,24 |
| PRIMECAP Management Co. | 0,79 |
| Flossbach von Storch SICAV - Multiple Opportunities | 0,78 |
| Vanguard Developed Markets Index Fund | 0,65 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2016 | 2017 | 2018 | 2019 | 2020 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 94.052 | 93.734 | 94.442 | 97.735 | 101.465 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,54 | 0,57 | 0,60 | 0,63 | 0,57 |
Bilanz (in Mio. EUR) - Aktiva
| 2016 | 2017 | 2018 | 2019 | 2020 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 28.670 | 31.572 | 32.244 | 31.254 | 32.942 |
| Summe Anlagevermögen | 46.266 | 45.401 | 46.392 | 48.329 | 51.752 |
| Summe Aktiva | 76.819 | 76.676 | 78.517 | 83.091 | 86.138 |
Bilanz (in Mio. EUR) - Passiva
| 2016 | 2017 | 2018 | 2019 | 2020 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 22.355 | 18.960 | 18.770 | 15.582 | 15.411 |
| Summe Fremdkapital | 50.417 | 47.669 | 48.151 | 47.224 | 46.365 |
| Summe Eigenkapital | 26.402 | 29.007 | 30.366 | 35.867 | 39.773 |
| Summe Passiva | 76.819 | 76.676 | 78.517 | 83.091 | 86.138 |
Adresse
| Grenzacherstrasse 124, 4070 Basel | |
| Telefon | +41 (61) 688-11-11 |
| Fax | +41 (61) 691-93-91 |
| Internet | http://www.roche.com |
Management
|
Alan Hippe
Chief Financial & Information Technology Officer |
|
André S. Hoffmann
Vice Chairman |
|
Anita Hauser
Director |
|
Bernard J. Poussot
Non-Executive Director |
|
Christoph Franz
Chairman |
|
Claudia Süssmuth Dyckerhoff
Director |
|
Cristina A. Wilbur
Head-Group Human Resources |
|
Gallia G. Levy
Associate Group Medical Director-Hematology |
|
Gottlieb A. Keller
Secretary & General Counsel |
|
Hans Clevers
Director |
|
Jason S. Ehrlich
Senior Group Medical Director |
|
Jorg Duschmale
Director |
|
Julie Brown
Director |
|
Karl Mahler
Head-Investor Relations |
|
Karsten Jung
Global Product Strategy Head |
|
Michael D. Varney
Head-Genentech Research & Early Development |
|
Pablo Umaña
Head-Cancer Immunotherapy Discovery |
|
Patrick Frost
Director |
|
Paul Bulcke
Non-Executive Director |
|
Per-Olof Attinger
Secretary-Executive Committee & Head-CEO Office |
|
Richard P. Lifton
Non-Executive Director |
|
Severin Schwan
Chief Executive Officer & Executive Director |
|
Urs Jaisli
Chief Compliance Officer |
|
William Pao
Head-Pharma Research & Early Development |
